PFE Today - Jul 09: AstraZeneca's Crash Boosts Rivals

カートのアイテムが多すぎます

ご購入は五十タイトルがカートに入っている場合のみです。

カートに追加できませんでした。

しばらく経ってから再度お試しください。

ウィッシュリストに追加できませんでした。

しばらく経ってから再度お試しください。

ほしい物リストの削除に失敗しました。

しばらく経ってから再度お試しください。

ポッドキャストのフォローに失敗しました

ポッドキャストのフォロー解除に失敗しました

PFE Today - Jul 09: AstraZeneca's Crash Boosts Rivals

無料で聴く

ポッドキャストの詳細を見る

Hey there! It’s Joey, your friendly investor buddy. Let’s break down what went down with Pfizer today. So, PFE had a pretty chill day, closing up just a little, like 0.54%. Not exactly fireworks, but hey, it’s something, right?

So, here’s the scoop. Pfizer didn’t have a huge move on its own, but it kinda rode the coattails of AstraZeneca’s rough day. AstraZeneca took a dive, crashing about 8%. That’s a big deal! When one of your rivals gets smoked like that, it can give others a little boost. Pfizer and a couple of other competitors saw some green as folks shifted their focus. It’s like the old saying goes—when one ship sinks, others might float a bit higher.

Now, why did AstraZeneca crash? Well, it looks like they had some bad news that spooked investors. Not exactly the best headlines for them, and that ripple effect gave Pfizer a little lift. But let’s be real, nobody's really popping champagne over a 0.54% gain. It’s more like a gentle nudge forward rather than a major win.

Oh, and here’s something interesting on the horizon. Pfizer's Lyme disease vaccine is showing some solid promise, with reports saying it has 70% efficacy. That’s some good news, especially considering the whole vaccine game is still a hot topic. It might not be a game-changer right away, but it’s definitely something to keep an eye on.

So, to wrap it up, Pfizer had a bit of a quiet day, but it got a slight lift thanks to AstraZeneca’s misfortune. Not the most exciting movement, but hey, every little bit counts, right? Just remember, this is all for your info and entertainment—no financial advice here. Catch you later!

まだレビューはありません